BioNxt Solutions Prepares for Human Bioequivalence Study For MS
23.4.2025 03:05:00 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
U.S. Air Force Awards GA-ASI Production Contract for FQ-42A CCA18.6.2026 00:10:00 CEST | Press release
Company Will Produce Service's New Uncrewed Combat Jets SAN DIEGO, CA / ACCESS Newswire / June 17, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has received a production contract from the U.S. Air Force (USAF) for the FQ-42A Collaborative Combat Aircraft (CCA). The initial order is a significant milestone, beginning the delivery of production aircraft to the warfighter. GA-ASI designed, developed and flight-tested FQ-42A on an accelerated schedule unlike any fighter in recent history. "This is an exciting day for our company and the nation," said company President David R. Alexander. "Moving to production on FQ-42A is the result of an extraordinary partnership and many years of investments between General Atomics and the U.S. Air Force. We've been preparing for this order, and manufacturing is already well underway." The FQ-42A is a purpose-built, uncrewed fighter developed as part of ongoing investment in next-generation semi-autonomous combat aircraft. The aircraft's mo
Polaris Renewable Energy Announces Postponement of Annual Meeting of Shareholders17.6.2026 23:30:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 17, 2026 / Polaris Renewable Energy Inc. (the "Corporation" or "Polaris") today announced that its annual meeting of shareholders (the "Meeting"), originally scheduled to be held on June 18, 2026 at 9:00 a.m. (Toronto time), has been postponed. The Meeting will now be held as follows: Date: June 26, 2026 Time: 9:00 a.m. (Toronto time) Format: Virtual-only meeting Webcast: https://virtual-meetings.tsxtrust.com/1923 Password: "polaris2026" The Meeting will be conducted in the same virtual format as previously announced, and shareholders will continue to be able to attend, participate and vote online through the TSX Trust virtual meeting platform. Purpose of Postponement The postponement is being done as the required quorum of 50.1% of shareholders voting has not been achieved at this point in time. We encourage shareholders that have not yet voted their shares to do so prior to 9 am on June 25th. Meeting Materials and Business The business of the Meet
Innodata Appoints Jayant Chauhan as Chief Financial Officer17.6.2026 22:30:00 CEST | Press release
Brings More Than Two Decades of Experience in Finance and Scaling High-Growth Technology Companies, Effective July 6, 2026 Interim CFO Marissa Espineli to Transition to Chief Accounting Officer NEW YORK, NY / ACCESS Newswire / June 17, 2026 / INNODATA INC. (Nasdaq:INOD) ("Innodata" or the "Company") today announced that it has appointed Jayant Chauhan as Executive Vice President and Chief Financial Officer (CFO), effective July 6, 2026. At that time, Marissa Espineli, who is serving as the Company's Interim Chief Financial Officer, will transition to the new role of Chief Accounting Officer, reporting to Mr. Chauhan. Mr. Chauhan brings to Innodata more than two decades of experience building and leading finance functions for fast-growing global technology companies. He most recently served as Senior Vice President, M&A at Mphasis, a Blackstone-owned, publicly traded global IT services company, and previously as Senior Vice President, Global Strategic Finance, and CFO of the operated ho
Qualitest Becomes QualityAI: The Trusted Assurance and Engineering Partner Across Every Stage of Enterprise AI17.6.2026 18:45:00 CEST | Press release
As businesses double down on AI deployment, QualityAI helps enterprise leaders move beyond AI claims and go live with confidence. LONDON, UK / ACCESS Newswire / June 17, 2026 / Qualitest, the leading provider of AI-first quality engineering and assurance, today announces its rebrand to QualityAI. The new brand reflects the company's evolution from software testing specialist to AI-first quality engineering partner, helping enterprises design quality into complex systems from the outset. Across every industry, companies are racing to adopt AI, and the pressure to demonstrate progress is rising. According to Deloitte's 2026 "State of AI in the Enterprise" report, the proportion of organizations expecting at least 40% of AI experiments to reach production is expected to more than double within six months. As AI moves from ambition to implementation, leaders need to prove that transformation is real, reliable, and effective. In a market crowded with AI claims, assurance is becoming the dif
Skymantics Europe Joins BDVA to Overcome Data Scarcity Barriers in European AI Adoption17.6.2026 14:35:00 CEST | Press release
Providing fully GDPR-compliant synthetic population datasets to unlock paralyzed AI initiatives in Europe. ZARAGOZA, ES / ACCESS Newswire / June 17, 2026 / Skymantics Europe, developer of the DataGenesis™ AI software, today announced it has joined the Big Data Value Association (BDVA). This membership marks a pivotal step in Skymantics Europe's mission to help overcome one of the major barriers to European AI adoption, namely "data scarcity": availability of large quantities of high-quality data, compliant with GDPR and European AI Act. As European governments and businesses accelerate the AI adoption for complex decision-support environments, they face a recurring "Compliance Paradox": the need for high-fidelity data to drive innovation versus the legal requirement to protect citizen privacy. Skymantics Europe resolves this tension via DataGenesis™, its proprietary software engine that generates behavioral digital twins mathematically indistinguishable from production datasets, yet co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom